Videos

Fear of losing custody, self-blame, and not knowing the condition is treatable keep mothers silent. Clinicians can address each one directly.

Postpartum psychosis is a psychiatric emergency with a fluctuating, atypical presentation and a high risk of recurrence that clinicians can easily miss.

Learn how antipsychotic blood levels guide dosing, spot nonadherence, and set clozapine/haloperidol targets for better schizophrenia outcomes.

Ketogenic nutrition and insulin-targeted metabolic psychiatry may add a new tool for severe mental illness.

Learn why ketogenic metabolic therapy is a monitored medical treatment, not a fad diet, and how metabolic pathways may reshape mental health care.

Many symptoms that most impair patients with major depressive disorder go unspoken until treatment starts working, making early recognition and patient-defined goals central to effective care.

How insulin resistance, inflammation, and ketogenic therapy reshape treatment for bipolar and schizophrenia—inside the rise of metabolic psychiatry.

Depression's cardinal symptoms are often invisible to the patient reporting them. Dr. Harding and Dr. Citrome examine why diagnosis, not treatment, remains psychiatry's hardest task, and how family observation and screening for bipolar depression change the diagnostic path.

New evidence links hippocampal “internally generated” activity to memory and psychosis, suggesting new network-based models for schizophrenia.

Hippocampal “tuplets” build predictive sequences; sleep rapidly rewires schemas for insight learning, offering clues to schizophrenia hallucinations.

Extended-release stimulants have become first-line therapy for adult ADHD, replacing outdated practices that once set patients up for failed medication trials. The panel explains why.

Deciding when and how to change a schizophrenia treatment plan requires curiosity, comparative evidence, and careful sequencing. The panel discusses long-acting injectables, combination strategies, and when clozapine becomes the right next step.

From long-acting injectables to rational combination therapy, the panel maps today's treatment landscape, weighing efficacy against adverse events and stressing the

ADHD rarely confines itself to one area of an adult's life. The panel traces how the condition's burden compounds across work, family, and relationships as responsibilities grow.

Xanomeline-trospium targets muscarinic receptors for schizophrenia relief with fewer side effects, and early data suggest cognitive gains.

Cobenfy revived shelved muscarinic therapy for schizophrenia, easing side effects while boosting negative and cognitive symptoms across trials.

Most depression in this country is never treated by a psychiatrist. The panel maps which parts of the journey primary care can own, where handoffs break down, and what safety demands first.

The imaging evidence is associational, not causal. The panel weighs whether that is reason enough for a skeptical colleague to treat depression earlier, and how anxiety complicates the picture.

Experts urge caution prescribing GLP-1s for patients with eating disorders, highlighting motivation checks, psychoeducation, and team-based care.

Safety data, not just efficacy, determines how comfortable clinicians feel prescribing. The panel reviews the safety profile, dosing schedule, and drug interactions relevant to a newer agitation therapy.

Pivotal trial data can reshape when clinicians feel comfortable starting treatment. The panel walks through the short- and long-term study results behind a newer agitation therapy in detail.

GLP-1 weight-loss drugs may aid binge eating, but clinicians must screen for eating disorders and monitor patients with multidisciplinary care.

Explore how TMS might be useful in treating schizophrenia, and how researchers are working to localize target areas.

Causal lesion and stimulation studies map psychosis to hippocampus–thalamus circuits, pointing to a reproducible TMS target for schizophrenia symptoms.

Adolescent synaptic pruning may fuel schizophrenia; researchers explore how restoring plasticity could ease fixed delusions.

Primate brain tissue studies track pruning, myelination, and dopamine across development, revealing adolescence-linked neural dynamics that may explain schizophrenia risk.

Learn how to launch TMS or Spravato services—costs, billing, REMS logistics, training, and what’s next in interventional psychiatry.

After 2 antidepressant trials, TMS or esketamine offers faster relief and durable remission—see why clinicians switch sooner.

See how telehealth, teach-back, and trusted community education boost health literacy and tackle social determinants.

Untreated ADHD carries measurable costs in relationships, careers, and even life expectancy. The panel makes the clinical case for diagnosing and treating adult ADHD as early as possible.